Skip to main content

Table 2 Univariate analysis of variables associated with overall survival in patients undergoing repeat TACE, with baseline variables (a) and subsequent to initial TACE (b)

From: Prognostic role of alpha-fetoprotein in patients with hepatocellular carcinoma treated with repeat transarterial chemoembolisation

 Overall cohort n = 292  
 Hazard RatioLower 95% CIHigher 95% CIP value
Pre -TACE
Variable
Single Tumour0.760.591.000.043
Albumin, g/L0.960.940.98<0.001
Bilirubin, μmol/L1.021.011.03<0.001
Ascites1.941.352.78<0.001
Hepatic Encephalopathy1.700.992.900.048
BCLC stage A0.750.580.970.026
BCLC stage B1.361.041.770.020
Child Pugh Score (5/6/7/8/9)1.251.131.39<0.001
AFP ≥ 200 ng/ml1.481.072.040.015
Post-TACE
Variable
Post 1st TACE
 AFP ≥ 200 ng/ml2.191.433.36<0.001
 Albumin, g/L0.950.930.98<0.001
 Bilirubin, μmol/L1.021.011.03<0.001
 Na, mmol/L0.950.910.990.010
 INR1.701.122.590.012
 MELD score1.071.021.110.004
 Child Pugh Score (5/6/7/8/9)1.291.161.43<0.001
 Ascites1.661.172.350.004
Post 2nd TACE
 Decompensation3.391.856.21<0.001
 Renal dysfunction3.461.0711.190.035
Combination therapy0.650.460.910.011
 Ablation0.560.350.880.011
 Resection0.270.100.760.011